Re. There is no reason or purpose atm for additional funds
The single biggest bottleneck IMO to achieve share price appreciation is speed of execution: RAC needs to significantly derisk by moving as many existing pillars toward end of clinical trials - and also materialise revenue opportunities by working on more pillars.
I cannot help but think that more well-spent capital could help RAC to deliver value quicker, in one way or another. Right now with a market cap of ~230M, RAC's annual budget of ~4-5M seems very shy and could get a little cash boost without diluting too much (especially if done with existing shareholders using a SPP). Granted, wombat previously hinted that the Board does not wish to diluate capital more than necesary.
Of course, I am biased. As an investor, I tend to look at 12-24 months return window max. I really wish to see significant SP progress on the back of FTO and Breast Cancer pillars by then.
RAC - Charts & Price Action, page-2997
-
- There are more pages in this discussion • 18,971 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.050(3.33%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.55 | $1.49 | $86.32K | 57.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4520 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 2259 | 1 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |